



## **Byotrol Limited**

("Byotrol" or the "Company")

### **Trading Update**

Byotrol, the specialist infection and prevention control company, is pleased to announce an update on trading.

Results for the year ended 31 March 2025 (FY25), subject to audit, are expected to be reported as follows:

- Total Sales of £4.324m (vs FY24: £3.970m)
- Total Gross Margin: 49.5% (vs FY24: 43.2%, excluding disposal costs of obsolete and discontinued stock)
- Product sales\* of £3.869m (vs FY24: £3.902m)
- Product Sales Gross Margin 43.6% (vs FY24: 43.2%, excluding disposal costs of obsolete and discontinued stock)
- Adjusted EBITDA of -£0.100m (vs FY24: -£0.968m)
- Closing cash of £421k (vs FY24: £315k)

In the final quarter of FY25, we concluded the sale of 2 formulations combined with a 5-year licence agreement to our trading partner in Japan for £425k. The sale of these formulations, no longer used by Byotrol in the UK or elsewhere, provides important continuity of supply to our partner given the increased challenge of securing some of the raw materials required here in the UK, whilst also providing Byotrol with an important boost in both cash and profit for the year.

Whilst product sales closed slightly behind FY24, this owed to a difficult Q1 where, as previously mentioned, our sales were suppressed due to significant inventory in the channel following the push in the final quarter of FY24. Q2 to Q4 show year on year growth, giving us a platform from which to progress as we move into the new financial year.

Overall, we remain extremely positive about our position but are well aware that there is much more work to be done. After experiencing an extended period of decline post-Covid, it is clear that the business has finally turned a corner and, since the beginning of Q2 FY25, has started to grow again, marking the end of the first step of our turnaround. The focus now is to accelerate this growth, progress to cash breakeven as quickly as we can, and then onwards to profitability. In doing so, we will be able to transform the valuation of the Company against its current state and return long-awaited value to stakeholders and shareholders alike.

For further information visit [www.byotrolplc.com](http://www.byotrolplc.com) or contact

#### **Byotrol Ltd**

Ashley Head, Non-Executive Chairman  
Chris Sedwell, Managing Director

+44 (0)1925 742 000

#### **Asset Match**

Ben Weaver  
Hannah Woodley

+44 (0)207 248 2788

\* before recharges/other income

Notes to Editors:

*Byotrol Ltd is a specialist infection prevention and control company, operating globally in animal health, human health, consumer products and facilities management sectors. Byotrol develops and commercialises innovative biocidal technologies and brands which provide targeted protection against harmful pathogens.*

*For more information about Byotrol plc please visit [byotrolplc.com](https://byotrolplc.com) and [follow the company on LinkedIn](#).*

*For information on Byotrol products and customers please visit [byotrol.com](https://byotrol.com)*

[END]